Bortezomib-containing multimodality treatment for antibody-mediated rejection with anti-HLA and anti-AT1R antibodies after kidney transplantation by Iesari, Samuele et al.
679www.eymj.org
To the Editor:
For decades, the human leukocyte antigen (HLA) complex 
has been considered the primary target of antibody-mediated 
rejection (AMR), and treatment strategies have mainly fo-
cused on anti-HLA antibodies. Recently, other antibodies po-
tentially causing organ damage and loss have been discov-
ered. Conclusive evidence on treatment options for these sub-
types of AMR is still lacking. After an experience previously 
reported in this journal,1 we describe a case of late-onset AMR, 
with mixed anti-HLA and anti-angiotensin II type 1 receptor 
(AT1R) antibodies, that was successfully treated with a multi-
modal approach, including the use of the proteasome inhibi-
tor bortezomib.
A 39-year-old Caucasian man received a live-related renal 
transplant in 2007. The donor and the recipient were blood 
group compatible with a 5 ABDRDQ-HLA-antigen mismatch. 
Pre-transplant panel reactivity antibody and direct microcy-
totoxicity cross-match were negative. For baseline immuno-
suppression, the patient received basiliximab, tacrolimus, en-
teric-coated mycophenolate sodium, and steroids. Postopera-
tive course and follow up were uneventful. Seven years after 
transplantation, the patient was hospitalized with worsening 
graft function and low calcineurin inhibitor levels (Table 1), 
reflecting occasional non-compliance with immunosuppres-
sants. Antibody screening showed anti-HLA sensitization, with 
de novo donor-specific antibodies (DSAs) against B58 and 
DQ9, and high titers of anti-AT1R antibodies (>50 U/L). Inter-
estingly, both anti-HLA DSAs were unable to fix C1q, suggest-
ing that anti-AT1R antibodies played a toxic role, in this specific 
setting. Histopathologic examination confirmed AMR. The pa-
tient received an initial multimodality treatment based on a 
combination of steroids, plasma exchange, and intravenous 
immunoglobulins. Then, bortezomib (Velcade®, Takeda, Osaka, 
Japan) was administered at 1.3 mg/m2 of body surface area, on 
days 1, 4, 8, and 11, to directly inhibit antibody production th-
rough plasma cell depletion.2 Following anti-rejection treat-
ment, anti-HLA DSA and anti-AT1R antibodies promptly dis-
appeared, and SCr stably decreased. One year later, the patient 
is doing fine, with stable graft function, no proteinuria, and 
undetectable DSA and anti-AT1R antibodies (Table 1).
Despite surgical innovations and novel immunosuppressive 
regimens, long-term kidney allograft survival has not signifi-
cantly improved during last decades, since we are now losing 
organs mainly due to AMR.3 Recently, in addition to anti-HLA 
antibodies, new antibodies have been discovered in trans-
plant recipients experiencing rejection, supporting the hy-
pothesis that anti-HLA antibodies may not be the only effectors 
of alloimmune humoral response. Among them, anti-AT1R 
antibodies seem to be particularly significant. 
AT1R is the main receptor for angiotensin II. Anti-AT1R an-
tibodies can mimic angiotensin II and trigger multiple autore-
active and alloreactive responses, eventually leading to cell 
damage, apoptosis, and hypertension due to allosteric activa-
tion of AT1R.4 Anti-AT1R antibodies can act independently or 
synergistically with other effectors of the rejection pathway.5
Our patient experienced AMR seven years after transplanta-
tion due to non-compliance. An association between anti-HLA 
and anti-AT1R antibodies has been already described in un-
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der-immunosuppressed kidney transplant recipients.5 De 
novo anti-AT1R antibodies have been also detected after epi-
sodes of allosensitization,6 being consistently associated with 
rejection and poor graft and patient survivals.7 However, testing 
for non-anti-HLA antibodies is not routinely performed, such 
that their real incidence and prevalence in the transplant popu-
lation are basically unknown.7 
What may trigger the development of anti-AT1R antibodies 
after transplantation is still under investigation. Several fac-
tors have been proposed: 1) genetic polymorphisms affecting 
the structure of AT1R extra-cellular domain; 2) genetic poly-
morphisms altering the geometric shape of the receptor; 3) an-
tigenic exposure secondary to death perturbations; and 4) cell 
damage caused by alloimmune response, which modifies AT1R 
expression into the graft exposing previously hidden epitopes.5
Meanwhile, several therapeutic options have been proposed 
to treat early-onset anti-HLA AMR. Some combination strate-
gies have shown good results in the short term, although no 
clear benefit of one specific regimen has been demonstrated, 
and long-term results are sub-optimal. Experience with late-
onset non-anti-HLA AMR is even more limited.8 Inhibition of 
B-cells and antibody production by administration of anti-
CD20 monoclonal antibodies (e.g., rituximab) or proteasome 
inhibitors (e.g., bortezomib) may represent a promising option 
together with apheretic techniques and intravenous immu-
noglobulins.9
Optimal treatment of late-onset acute AMR is still a matter 
of debate. Reports on anti-AT1R AMR are anecdotal: some au-
thors support the role of apheresis combined with intrave-
nous normal human immunoglobulins, rituximab, and high-
dose AT1R-blockers.10 This journal has already published a 
first successful experience with bortezomib.1 Our experience 
with a multimodality treatment, including bortezomib, con-
firms its efficiency in stably clearing not only anti-HLA but also 
anti-AT1R antibodies, halting renal function deterioration 
even in the longer term.
Further investigations are warranted to better address the 
role of proteasome inhibition in the setting of anti-HLA and 
non-anti-HLA AMR and to assess the contribution of bortezo-
mib to overall efficacy.
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Normal
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Before
rejection
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DSA DQ9 (MFI) / - 3800 - - - - - - -
Anti-AT1R Abs (U/l) / - >50 - - - 14 - 0 0
Prednisone (mg/day) / 5 5 20 20 20 20 10 10 10
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Tacrolimus (mg/day) / 3 3 5 5 5 5 6.5 5.5 5.5
Tacrolimus C0 (ng/mL) / 6.1 3.2 5.6 6.8 4.4 5.2 8.3 5.7 4.6
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Abs, antibodies; AT1R, anti-angiotensin II type 1 receptor; C0, trough level; CRP, C-reactive protein; DSA, donor-specific antibodies; eGFR, estimated glomerular filtra-
tion rate; HLA, human leukocyte antigen; MFI, mean fluorescence intensity; NLR, neutrophil-to-lymphocyte ratio; WCC, white cell count.
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